These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 34732117)

  • 1. Comparison of Metformin-sulfonylurea and Metformin-acarbose Combination Therapies on Glycemic Outcomes: A Retrospective Cohort Study.
    Wafa W; Septini R; Sauriasari R
    Curr Diabetes Rev; 2022; 18(7):e031121197656. PubMed ID: 34732117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
    Bayraktar M; Van Thiel DH; Adalar N
    Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
    Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
    Sun W; Zeng C; Liao L; Chen J; Wang Y
    Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.
    López-Alvarenga JC; Aguilar-Salinas CA; Velasco-Perez ML; Arita-Melzer O; Guillen LE; Wong B; Brito G; Mercado V; Gómez-Pérez FJ; Rull-Rodrigo JA
    Diabetes Obes Metab; 1999 Jan; 1(1):29-35. PubMed ID: 11221809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Diabetes Care; 1998 Oct; 21(10):1612-8. PubMed ID: 9773719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
    J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
    Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV
    Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels.
    Zhang JP; Wang N; Xing XY; Yang ZJ; Wang X; Yang WY
    J Diabetes; 2016 Jul; 8(4):559-67. PubMed ID: 26331290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
    Chen YH; Tarng DC; Chen HS
    PLoS One; 2016; 11(11):e0165750. PubMed ID: 27812149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study.
    Willms B; Ruge D
    Diabet Med; 1999 Sep; 16(9):755-61. PubMed ID: 10510952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
    Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
    J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.